Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Home Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

/ Publications

Share the Post

About the Author

Related Posts

nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology
Read More
Neil Desai, PhD
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Read More
Behzad Aghazadeh, PhD
Read More
Scott Giacobello, CPA

Comments

Comments are closed.